Traduction de «products and amending » (Néerlandais → Français) :

TERMINOLOGIE

product dat aescine bevat
produit contenant de l'aescine

product dat balsalazide bevat
produit contenant du balsalazide

product dat bacitracine bevat
produit contenant de la bacitracine

product dat basiliximab bevat
produit contenant du basiliximab

product dat baclofen bevat
produit contenant du baclofène

product dat auranofine bevat
produit contenant de l'auranofine

product dat auranofine in orale vorm bevat
produit contenant de l'auranofine sous forme orale

product dat enkel auranofine in orale vorm bevat
produit contenant seulement de l'auranofine sous forme orale

product dat barbituraat bevat
produit contenant du barbiturique

product dat baricitinib bevat
produit contenant du baricitinib

TRADUCTIONS EN CONTEXTE

De Europese Commissie heeft een voorstel tot “Directive of the European Parliament and of the Council amending, as regards information to the general public on medicinal products subject to medical prescription, Directive 2001l83/EC on the Community code relating to medicinal products for human use” goedgekeurd (bijlage).
La Commission européenne a déposé une proposition de “Directive of the European Parliament and of the Council amending, as regards information to the general public on medicinal products subject to medical prescription, Directive 2001/83/EC on the Community code relating to medicinal products for human use” (cf. annexe).

At European level, important texts were adopted such as Directive 2007/47/EC amending Directive 93/42/EEC concerning medical devices and Directive 90/385/EEC on the approximation of the laws of the Member States relating to active implantable medical devices, and Regulation (EC) no. 1394/2007 on advanced therapy medicinal products.
At European level, important texts were adopted such as Directive 2007/47/EC amending Directive 93/42/EEC concerning medical devices and Directive 90/385/EEC on the approximation of the laws of the Member States relating to active implantable medical devices, and Regulation (EC) no. 1394/2007 on advanced therapy medicinal products.

Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. [http ...]
Directive 2004/27/CE du Parlement européen et du Conseil du 31 mars 2004 modifiant la directive 2001/83/CE instituant un code communautaire relatif aux médicaments à usage humain, JO L 136 du 30 avril 2004, pp.0034-0057 ( [http ...]

Amendments to the Law of 20 July 2006 on the establishment and functioning of the Federal Agency for Medicines and Health Products (art. 109).
Amendments to the Law of 20 July 2006 on the establishment and functioning of the Federal Agency for Medicines and Health Products (art. 109).

Amendments to the Law of 20 July 2006 on the establishment and functioning of the Federal Agency for Medicines and Health Products (art. 178-180).
Amendments to the Law of 20 July 2006 on the establishment and functioning of the Federal Agency for Medicines and Health Products (art. 178-180).

Op 30 december 2008 trad binnen de Europese Unie een nieuwe regelgeving inzake geneesmiddelen voor geavanceerde therapie (advanced therapies) in voege (Regulation (EC) No 1394/2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004).
Op 30 december 2008 trad binnen de Europese Unie een nieuwe regelgeving inzake geneesmiddelen voor geavanceerde therapie (advanced therapies) in voege (Regulation (EC) No 1394/2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004).

The FAMHP’s Marketing authorisation Department is responsible for evaluating new applications and requests for amendments to existing marketing authorisation (MA) with a view to granting authorisation for marketing a medicine or health product.
The FAMHP’s Marketing authorisation Department is responsible for evaluating new applications and requests for amendments to existing marketing authorisation (MA) with a view to granting authorisation for marketing a medicine or health product.